| Effect | Decrease |
| Values | The low-FODMAP group reported lower scores for flatulence (0.9, SEM 0.1 versus 1.2, SEM 0.1; p=0.012). |
| Trial Design | Randomized trial |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 52 |
| Sex | Both Genders |
| Age Range | 18-29, 30-44, 45-64 |
| Body Types | Overweight, Average |
In this randomized controlled trial, 52 patients with Crohn’s disease or ulcerative colitis were assigned to a low-FODMAP or control diet with dietary advice for 4 weeks.Funding issues for this study:
Gut symptoms, health-related quality of life (QoL), fecal microbiome composition and function, and T-cell phenotypes were analyzed at baseline and after 4 weeks.
A greater proportion of patients reported adequate symptom relief on the low-FODMAP diet compared to the control diet. The reduction in IBS symptom severity score was not significantly different between the groups, but the low-FODMAP group reported lower scores for bloating and flatulence. Patients following the low-FODMAP diet reported higher QoL scores.
Abundances of specific species were lower in the low-FODMAP group at the end of the study period, but relative abundance of the Bifidobacterium genus, microbiome diversity and inflammatory markers did not differ between groups.
Fecal concentrations of total SCFA were lower following the low-FODMAP diet compared with the control diet.
Absolute numbers or proportions of T-cell phenotypes did not differ between diets at the end of the trial.
Two authors are co-inventors of a low-FODMAP diet mobile app, and one of these authors also received consultancy fees from Danone and a research grant from Clasado.
